CJC-1295 without DAC + Ipamorelin (10MG)

Description

CJC-1295 without DAC + Ipamorelin is a dual-peptide research formulation combining CJC-1295 without DAC (Modified GRF 1-29), a GHRH receptor agonist, with Ipamorelin, a selective ghrelin receptor (GHSR-1a) agonist. The two compounds act on distinct but complementary receptor pathways in growth hormone regulation, making this blend a research tool for studying synergistic GHRH/ghrelin pathway activation in vitro.

Molecular Profile
Components: CJC-1295 without DAC (Modified GRF 1-29) + Ipamorelin (CAS 170851-70-4)
CJC-1295 without DAC Molecular Weight: ~3,370 Da
Ipamorelin Molecular Weight: 711.87 Da
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water

View COA

Research Context
CJC-1295 without DAC acts on the pituitary GHRH receptor to stimulate GH release via cAMP-dependent pathways, while Ipamorelin engages the GHSR-1a receptor through the ghrelin pathway with high selectivity for GH over ACTH, prolactin, and cortisol. Their complementary mechanisms have been characterized in peer-reviewed literature as a model for studying additive and synergistic GH secretion dynamics in vitro. Research applications include dual receptor specificity studies and pituitary signaling cascade analysis.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.